Traetment of Enteric Diseases with Point-injection Therapy at Changqiang

ＴｒａｅｔｍｅｎｔｏｆＥｎｔｅｒｉｃＤｉｓｅａｓｅｓｗｉｔｈＰｏｉｎｔ－ｉｎｊｅｃｔｉｏｎＴｈｅｒａｐｙａｔＣｈａｎｇｑｉａｎｇ￥ＨｕａｎｇＹａｏｙｕａｎ（ＺｈａｎｇｚｈｏｕＣｉｔｙ＇ｓＨｏｓｐｉｔａｌｏｆＴｒａｄｉｔｉｏｎａｌＣｈｉｎｅｓｅＭｅｄｉ...

APPLICATION OF ACUPOINT-INJECTION THERAPY TO PAIN SYNDROME: CLINICAL ANALYSIS OF 250 CASES

In this paper,250 cases of headache,shoulder pain,lumbago and leg pain weretreated with 20％Angelicae Sinensis mixed with Vitamine B12 point-injection therapy.The total effective rate was 95.2％and in which the cure rate was 53.6％.Authors have found a close correlation between the effectiveness and the duration of disease.

Therapeutic Effects of the Point-injection Therapy on Primary Trigeminal Neuralgia An Observation of 103 Cases

From 1996 to 1999, the author treated 103 cases of primary trigeminal neuralgia by point-injection with lidocaine, VB1 and VB12, and obtained quite good therapeutic results. A report follows.

Observations on Curative Effect of High-frequency Electric Sparkle and Point-injection Therapy on Knee Osteoarthritis

Objective: To observe the curative effect of high-frequency electric sparkle and point-injection therapy (HESPT) on knee osteoarthritis (KOA). Methods: Two hundred and five patients were randomly divided into a warming needle moxibustion group (68 cases), a HESPT group (68 cases) and a point-injection group (69 cases). In the warming needle moxibustion group, the main points of Xuehai (SP 10), Neixiyan (EX-LE4), Waixiyan (EX-LE5), Dubi (ST 35), Zusanli (ST 36) and Yanglingquan (GB 34), and the adjunct points of Yinlingquan (SP 9) and Sanyinjiao (SP 6), on the affected side, were chosen for stimulation. In the HESPT group, tenderness points, the main points of Liangqiu (ST 34), Xuehai (SP 10), Neixiyan (EX-LE4), Waixiyan (EX-LE5) and Zusanli (ST 36), and the adjunct points of Yinlingquan (SP 9), Weizhong (BL 40) and Chengshan (BL 57), were chosen. After proper manipulation, Corydalis decumbens Pers. liquid was injected into the points and a high-frequency electric sparkle was applied to stimulate the needles for 30 seconds. In the point-injection group, point injection was performed with the same method, but the patients did not receive electric stimulation. The Western Ontario and McMaster University Osteoarthritis Index (WOMAC), the Lysholm Knee Score Scale (LKSS) and the ROM (Range of Motion) scale were used to evaluate the severity of KOA and the function of knee joints before treatment and 4 weeks after treatment. Finally, the Nimodipine method was used to assess the total curative effect. Results: After HESPT treatment, the scores for pain, morning stiffness and swelling were significantly lower (P<0.01) and LKSS index and ROM were much higher (P<0.01 and P<0.05 respectively) compared to the two other groups. The obviously effective rate and total effective rate were also significantly higher in the HESPT group than in the two other groups (P<0.01 or P<0.05). Conclusion: HESPT can improve joint function in KOA patients, and the curative effect is better than for warming needle moxibustion or point-injection only.

ACUPUNCTURE THERAPY AND POINT-INJECTION OF MEDICINE FOR TREATMENT OF 32 CASES OF INFANTILE CEREBRAL PALSY

In the present study, 32 cases of infantile cerebral palsy were treated with acupunc-ture and point-injection therapies. Among them, 15 cases were cured basicaly, 7 markedly efec-tive, 9 improved and 2 failed, with a total effective rate being 93. 8%. The results showed thatthe therapies both could improve the microcirculation of the brain tissues in favour of recovery ofcerebral functions.

Treatment of spinal cord injury with biomaterials and stem cell therapy in non-human primates and humans

Spinal cord injury results in the loss of sensory,motor,and autonomic functions,which almost always produces permanent physical disability.Thus,in the search for more effective treatments than those already applied for years,which are not entirely efficient,researches have been able to demonstrate the potential of biological strategies using biomaterials to tissue manufacturing through bioengineering and stem cell therapy as a neuroregenerative approach,seeking to promote neuronal recovery after spinal cord injury.Each of these strategies has been developed and meticulously evaluated in several animal models with the aim of analyzing the potential of interventions for neuronal repair and,consequently,boosting functional recovery.Although the majority of experimental research has been conducted in rodents,there is increasing recognition of the importance,and need,of evaluating the safety and efficacy of these interventions in non-human primates before moving to clinical trials involving therapies potentially promising in humans.This article is a literature review from databases(PubMed,Science Direct,Elsevier,Scielo,Redalyc,Cochrane,and NCBI)from 10 years ago to date,using keywords(spinal cord injury,cell therapy,non-human primates,humans,and bioengineering in spinal cord injury).From 110 retrieved articles,after two selection rounds based on inclusion and exclusion criteria,21 articles were analyzed.Thus,this review arises from the need to recognize the experimental therapeutic advances applied in non-human primates and even humans,aimed at deepening these strategies and identifying the advantages and influence of the results on extrapolation for clinical applicability in humans.

Optimizing care for gastric cancer with overt bleeding:Is systemic therapy a valid option?

Gastric cancer(GC)and gastroesophageal junction cancer(GEJC)represent a significant burden globally,with complications such as overt bleeding(OB)further exacerbating patient outcomes.A recent study by Yao et al evaluated the effectiveness and safety of systematic treatment in GC/GEJC patients presenting with OB.Using propensity score matching,the study balanced the comparison groups to investigate overall survival and treatment-related adverse events.The study's findings emphasize that systematic therapy can be safe and effective and contribute to the ongoing debate about the management of advanced GC/GEJC with OB,highlighting the complexities of treatment decisions in these high-risk patients.

Human induced pluripotent stem cell-derived therapies for regeneration after central nervous system injury

In recent years,the progression of stem cell therapies has shown great promise in advancing the nascent field of regenerative medicine.Considering the non-regenerative nature of the mature central nervous system,the concept that“blank”cells could be reprogrammed and functionally integrated into host neural networks remained intriguing.Previous work has also demonstrated the ability of such cells to stimulate intrinsic growth programs in post-mitotic cells,such as neurons.While embryonic stem cells demonstrated great potential in treating central nervous system pathologies,ethical and technical concerns remained.These barriers,along with the clear necessity for this type of treatment,ultimately prompted the advent of induced pluripotent stem cells.The advantage of pluripotent cells in central nervous system regeneration is multifaceted,permitting differentiation into neural stem cells,neural progenitor cells,glia,and various neuronal subpopulations.The precise spatiotemporal application of extrinsic growth factors in vitro,in addition to microenvironmental signaling in vivo,influences the efficiency of this directed differentiation.While the pluri-or multipotency of these cells is appealing,it also poses the risk of unregulated differentiation and teratoma formation.Cells of the neuroectodermal lineage,such as neuronal subpopulations and glia,have been explored with varying degrees of success.Although the risk of cancer or teratoma formation is greatly reduced,each subpopulation varies in effectiveness and is influenced by a myriad of factors,such as the timing of the transplant,pathology type,and the ratio of accompanying progenitor cells.Furthermore,successful transplantation requires innovative approaches to develop delivery vectors that can mitigate cell death and support integration.Lastly,host immune responses to allogeneic grafts must be thoroughly characterized and further developed to reduce the need for immunosuppression.Translation to a clinical setting will involve careful consideration when assessing both physiologic and functional outcomes.This review will highlight both successes and challenges faced when using human induced pluripotent stem cell-derived cell transplantation therapies to promote endogenous regeneration.

CLINICAL ANALYSIS ON TREATMENT OF 40 CASES OF HYPERLIPEMIA WITH POINT-INJECTION OF RADIX SALVIAE MILTIORRZHIZAE INJECTION

In the present paper, the effect of point-injection of Radix Salviae Miltiorrhizae injectio on blood-lipid was observed in 65 cases of hyperlipemia. The 65 patients were divided into point-injection group (40 cases who were treated with point-injection of Radix Salviae Miltiorrhizae injectio and oral administration of Shujiangzhi) and control group (25 cases who were treated with oral administration of Shujiangzhi only). Results showed that the total effective rate of the point-injection group was significantly higher than that of the control group (P<0. 05); point-injection of Radix Salviae Miltiorrhizae injectio could effectively raise the level of HDL-C, decrease lower LDL-C and regulate estrogen level of women. The slow releasing action of red sage root solution in the topical acupoint region prolonged and enhanced its effect in lowering blood-lipid. There was a significant difference between the two groups in the effect of lowering blood-fat (P< 0. 01).

Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies

Pancreatic adenocarcinoma remains a most deadly malignancy, with an overall 5-year survival of 5%. A subset of patients will be diagnosed with potentially resectable disease, and while complete surgical resection provides the only chance at cure, data from trials of postoperative chemoradiation and/or chemotherapy demonstrate a modest survival advantage over those patients who undergo resection alone. As such, most practitioners believe that completion of multimodality therapy is the optimal treatment. However, the sequence of surgery, chemotherapy and radiation therapy is frequently debated, as patients may benefit from a neoadjuvant approach by initiating chemotherapy and/or chemoradiation prior to resection. Here we review the rationale for neoadjuvant therapy, which includes a higher rate of completion of multimodality therapy, minimizing the risk of unnecessary surgical resection for patients who develop early metastatic disease, improved surgical outcomes and the potential for longer overall survival. However, there are no prospective, randomized studies of the neoadjuvant approach compared to a surgeryfirst strategy; the established and ongoing investigations of neoadjuvant therapy for pancreatic cancer are discussed in detail. Lastly, as the future of therapeutic regimens is likely to entail patient-specific genetic and molecular analyses, and the treatment that is best applied based on those data, a review of clinically relevant biomarkers in pancreatic cancer is also presented.

When combination therapy isn't working: Emerging therapies for the management of inflammatory bowel disease

Although antagonists of tumor necrosis factor have resulted in major therapeutic benefits in inflammatory bowel disease, the magnitude and durability of response are variable. Similar to previously available drugs such as 5-aminosalicylates and immunomodulators, the therapeutic effect is not universal leaving many people searching for options. The development of newer agents has benefited from advances in the understanding of the pathophysiology of the disease. Uncontrolled activation of the acquired immune system has an important role, and lymphocytes, cytokines, and adhesion molecules are broadly targeted for therapeutic intervention. There is increasing evidence of an important role of the innate immune system and the intestinal epithelium, and the therapeutic paradigm is also shifting from immunosuppression to the reinforcement of the intestinal barrier, and modification of the disease process. In this review, we explore the limitation of current therapy as well as mechanisms of actions of new drugs and the efficacy and adverse events from data from clinical trials.

Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy

Hepatocellular carcinoma(HCC) is a common, increasingly prevalent malignancy. For all but the smallest lesions, surgical removal of cancer via resection or liver transplantation(LT) is considered the most feasible pathway to cure. Resection- even with favorable survival- is associated with a fairly high rate of recurrence, perhaps since most HCCs occur in the setting of cirrhosis. LT offers the advantage of removing not only the cancer but the diseased liver from which the cancer has arisen, and LT outperforms resection for survival with selected patients. Since time waiting for LT is time during which HCC can progress, locoregional therapy(LRT) is widely employed by transplant centers. The purpose of LRT is either to bridge patients to LT by preventing progression and waitlist dropout, or to downstage patients who slightly exceed standard eligibility criteria initially but can fall within it after treatment. Transarterial chemoembolization and radiofrequency ablation have been the most widely utilized LRTs to date, with favorable efficacy and safety as a bridge to LT(and for the former, as a downstaging modality). The list of potentially effective LRTs has expanded in recent years, and includes transarterial chemoembolization with drug-eluting beads, radioembolization and novel forms of extracorporal therapy. Herein we appraise the various LRT modalities for HCC, and their potential roles in specific clinical scenarios in patients awaiting LT.

Advances in radiotherapy and targeted therapies for rectal cancer

The last decade witnessed a significant progress in understanding the biology and immunology of colorectal cancer alongside with the technical innovations in radiotherapy.The stepwise implementation of intensitymodulated and image-guided radiation therapy by means of megavolt computed tomography and helical tomotherapy enabled us to anatomically sculpt dose delivery,reducing treatment related toxicity.In addition,the administration of a simultaneous integrated boost offers excellent local control rates.The novel challenge is the development of treatment strategies for medically inoperable patient and organ preserving approaches.However,distant control remains unsatisfactory and indicates an urgent need for biomarkers that predict the risk of tumor spread.The expected benefit of target?ed therapies that exploit the tumor genome alone is so far hindered by high cost techniques and pharmaceuticals,hence hardly justifying rather modest improvements in patient outcomes.On the other hand,the immune landscape of colorectal cancer is now better clarified with regard to the immunosuppressive network that promotes immune escape.Both N2 neutrophils and myeloid-derived suppressor cells(MDSC)emerge as useful clinical biomarkers of poor prognosis,while the growing list of anti-MDSC agents shows promising ability to boost antitumor T-cell immunity in preclinical settings.Therefore,integration of genetic and immune biomarkers is the next logical step towards effective targeted therapies in the context of personalized cancer treatment.

Combining chemotherapy and targeted therapies in metastatic colorectal cancer

Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, cetuximab and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer.

COMBINED TREATMENT OF 100 CASES OF SCIATICA WITH ACUPUNCTURE AND POINT-INJECTION

In the present paper, 160 cases of sciatica patients were divided into combined treatmentgroup (acupuncture plus point-injection, 100 cases) and acupuncture group (control group, 60 cases).After two courses of treatment, of the 100 cases in the combined treatment group, 72 (72% ) werecured, 25 (25 % ) effective and 3 (3 % ) had no effect, with an effective rate of 97%; Of the 60 casesin the control group, 30 (50 % ) were cured, 21 (35 % ) effective and 9 (15 % ) had no effect, with aneffective rate of 85 %. Statistical analysis showed a significant difference between the two groups in effective rate (P < 0. 05). It displayed that the effect of acupuncture plus point-injection was apparentlysuperior to that of acupuncture.

Thirty Cases of Acute Lumbar Sprain Treated by Acupuncture Combined with Point-Injection at Tianzhu

In recent years, the authors have treated 30 cases of acute lumbar sprain by acupuncture combined with point medicinal injection at Tianzhu (BL 10), and obtained quite good therapeutic results, as is reported in the following.

Revolutionizing gastric cancer treatment:The potential of immunotherapy

Gastric cancer,a prevalent malignancy worldwide,ranks sixth in terms of frequency and third in fatality,causing over a million new cases and 769000 annual deaths.Predominant in Eastern Europe and Eastern Asia,risk factors include family medical history,dietary habits,tobacco use,Helicobacter pylori,and Epstein-Barr virus infections.Unfortunately,gastric cancer is often diagnosed at an advanced stage,leading to a grim prognosis,with a 5-year overall survival rate below 5%.Surgical intervention,particularly with D2 Lymphadenectomy,is the mainstay for early-stage cases but offers limited success.For advanced cases,the National Comprehensive Cancer Network recommends chemotherapy,radiation,and targeted therapy.Emerging immunotherapy presents promise,especially for unresectable or metastatic cases,with strategies like immune checkpoint inhibitors,tumor vaccines,adoptive immunotherapy,and nonspecific immunomodulators.In this Editorial,with regards to the article“Advances and key focus areas in gastric cancer immunotherapy:A comprehensive scientometric and clinical trial review”,we address the advances in the field of immunotherapy in gastric cancer and its future prospects.

Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy:A case report and review of literature

BACKGROUND Hepatocellular carcinoma(HCC)is one of the leading causes of death due to its complexity,heterogeneity,rapid metastasis and easy recurrence after surgical resection.We demonstrated that combination therapy with transcatheter arterial chemoembolization(TACE),hepatic arterial infusion chemotherapy(HAIC),Epclusa,Lenvatinib and Sintilimab is useful for patients with advanced HCC.CASE SUMMARY A 69-year-old man who was infected with hepatitis C virus(HCV)30 years previously was admitted to the hospital with abdominal pain.Enhanced computed tomography(CT)revealed a low-density mass in the right lobe of the liver,with a volume of 12.9 cm×9.4 cm×15 cm,and the mass exhibited a“fast-in/fast-out”pattern,with extensive filling defect areas in the right branch of the portal vein and an alpha-fetoprotein level as high as 657 ng/mL.Therefore,he was judged to have advanced HCC.During treatment,the patient received three months of Epclusa,three TACE treatments,two HAIC treatments,three courses of sintilimab,and twenty-one months of lenvatinib.In the third month of treatment,the patient developed severe side effects and had to stop immunotherapy,and the Lenvatinib dose had to be halved.Postoperative pathological diagnosis indicated a complete response.The patient recovered well after the operation,and no tumor recurrence was found.CONCLUSION Multidisciplinary conversion therapy for advanced enormous HCC caused by HCV infection has a significant effect.Individualized drug adjustments should be made during any treatment according to the patient's tolerance to treatment.

CLINICAL OBSERVATION ON 134 CASES OF SEQUELAE OF POLIOMYELITIS TREATED WITH ACUPUNCTURE PLUS ACUPOINT-INJECTION

We had treated 134 cases of sequelae of poliomyelitis with acupuncture and acu-point-injection from 1989 to 1991. The patients’ ages ranged from 3 months to 2 years, and thecourses of disease were 3 days to 2 years. For most of cases, we had got a satisfactory effect after 3curative courses. The total effective rate was 91%. It indicates that the acupuncture plus acupoint-in-jection is a good method for treating the sequela of poliomyelitis.

Immunotherapy for esophageal cancer:Where are we now and where can we go

Immune checkpoint inhibitor therapy has dramatically improved patient prognosis,and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma(ESCC)in the past decade.Monoclonal antibodies that selectively inhibit programmed cell death-1(PD-1)activity has now become standard of care in the treatment of ESCC in metastatic settings,and has a high expectation to provide clinical benefit during perioperative period.Further,anti-cytotoxic T-lymphocyte–associated protein 4(CTLA-4)monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody.Well understanding of the existing evidence of immune-based treatments for ESCC,as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant,adjuvant,and metastatic diseases,may provide future prospects of ESCC treatment for better patient outcomes.